Search research articles
Contact Us
Filters
Showing results (11-20 of 19) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 19 results.
Radiation Oncology (London, England)
|
March 29, 2012
NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity
Emmanouil Fokas, Michio Yoshimura, Remko Prevo, et al.
Molecular Cancer Research : MCR
|
October 20, 2011
Inhibition of DNA-dependent protein kinase induces accelerated senescence in irradiated human cancer cells
Arun Azad, Susan Jackson, Carleen Cullinane, et al.
Cancer
|
October 19, 2006
Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer
Christopher Souder, Kim Leitzel, Suhail M Ali, et al.
Plos One
|
February 23, 2012
Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells
Christopher R Zito, Lucia B Jilaveanu, Valsamo Anagnostou, et al.
Cancer
|
June 14, 2005
Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy
Allan Lipton, Kim Leitzel, Suhail M Ali, et al.
Cancer Research
|
November 24, 2011
Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature
Emmanouil Fokas, Jae Hong Im, Sally Hill, et al.
Nanotechnology
|
August 7, 2012
Nano- and microstructuring of graphene using UV-NIL
Iris Bergmair, Wolfgang Hackl, Maria Losurdo, et al.
JAMA Oncology
|
June 15, 2018
Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial
Stephen J Luen, Rebecca Asher, Chee Khoon Lee, et al.
Cancer Chemotherapy and Pharmacology
|
June 9, 2018
Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer
Jordi Rodon, Alejandro Pérez-Fidalgo, Ian E Krop, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 19) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 19 results.
Radiation Oncology (London, England)
|
March 29, 2012
NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity
Emmanouil Fokas, Michio Yoshimura, Remko Prevo, et al.
Molecular Cancer Research : MCR
|
October 20, 2011
Inhibition of DNA-dependent protein kinase induces accelerated senescence in irradiated human cancer cells
Arun Azad, Susan Jackson, Carleen Cullinane, et al.
Cancer
|
October 19, 2006
Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer
Christopher Souder, Kim Leitzel, Suhail M Ali, et al.
Plos One
|
February 23, 2012
Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells
Christopher R Zito, Lucia B Jilaveanu, Valsamo Anagnostou, et al.
Cancer
|
June 14, 2005
Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy
Allan Lipton, Kim Leitzel, Suhail M Ali, et al.
Cancer Research
|
November 24, 2011
Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature
Emmanouil Fokas, Jae Hong Im, Sally Hill, et al.
Nanotechnology
|
August 7, 2012
Nano- and microstructuring of graphene using UV-NIL
Iris Bergmair, Wolfgang Hackl, Maria Losurdo, et al.
JAMA Oncology
|
June 15, 2018
Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial
Stephen J Luen, Rebecca Asher, Chee Khoon Lee, et al.
Cancer Chemotherapy and Pharmacology
|
June 9, 2018
Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer
Jordi Rodon, Alejandro Pérez-Fidalgo, Ian E Krop, et al.
Page
of 2